Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

by Wolfgang Hueber, Dhavalkumar D. Patel, Thaddeus Dryja, Andrew M. Wright, Irina Koroleva, Gerard Bruin, Christian Antoni, Zoe Draelos, Michael H. Gold, ,

Patrick Durez, Paul P. Tak, Juan J. Gomez-Reino, , C. Stephen Foster, Rosa Y. Kim, C. Michael Samson, Naomi S. Falk, David S. Chu, David Callanan, Quan Dong

Nguyen, , Kristine Rose, Asifa Haider, and Franco Di Padova

Sci Transl MedVolume 2(52):52ra72-52ra72

October 6, 2010

Published by AAAS

Fig. 1 Clinical response to AIN457 in patients with chronic plaque psoriasis.

Wolfgang Hueber et al., Sci Transl Med 2010;2:52ra72

Published by AAAS

Fig. 2 Immunohistochemistry of skin biopsies: Representative immuno-costaining of CD3 and IL-17.

Wolfgang Hueber et al., Sci Transl Med 2010;2:52ra72

Published by AAAS

Fig. 3 Gene expression changes in skin of patients with psoriasis treated with AIN457.

Wolfgang Hueber et al., Sci Transl Med 2010;2:52ra72

Published by AAAS

Fig. 4 ACR20, DAS28, and CRP changes for a two-dose infusion regimen of AIN457 (10 mg/kg) versus placebo.

Wolfgang Hueber et al., Sci Transl Med 2010;2:52ra72

Published by AAAS

Fig. 5 Vitreous haze (posterior segment uveitis) or anterior chamber cells (anterior uveitis) at week 8 versus week 0.

Wolfgang Hueber et al., Sci Transl Med 2010;2:52ra72

Published by AAAS